NImmune Biopharma Launches with Phase III-Ready Asset Gained from Landos Biopharma

by | Mar 22, 2023

Virginia life sciences entrepreneur Josep Bassaganya-Riera’s latest company NImmune Biopharma launched with an eye on a potential New Drug Application for its Phase III-ready experimental therapeutic for ulcerative colitis.

NImmune Biopharma’s lead asset is the clinical candidate omilancor, which it secured in February from Landos Biopharma, a company Bassaganya-Riera founded in 2017. Along with omilancor, NImmune gained the rights to Landos’ LANCL portfolio of immunoregulatory therapeutic assets, which also includes assets previously known as LABP-104 and LABP-111. These assets are designed to activate the Lanthionine Synthetase C-Like 2 (LANCL2) pathway, which enhances immunoregulatory processes that provide protection from autoimmune disease. Each of these assets were originally developed by Bassaganya-Riera, who served as chief executive officer of Landos until his departure from the company in November 2021.

Read More >

Recent Releases

Press Release
NImmune Biopharma Presents Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence 2023 (#ACR23)

NImmune Biopharma Presents Positive First-in-Human Data of NIM-1324, a Phase 2 Candidate for Systemic Lupus Erythematosus at the American College of Rheumatology Convergence 2023 (#ACR23)

First-in-human clinical trial of NIM-1324 met all primary and secondary endpoints Daily oral treatment with NIM-1324 is well-tolerated and safe with no dose-limiting toxicities Oral treatment with NIM-1324 induces a dose-proportional change in plasma exposure...

Read More

Press Release
NImmune Biopharma Announces Publication on the Safety, Efficacy and Novel LANCL2 Mechanism of Action of Omilancor in Inflammatory Bowel Diseases

NImmune Biopharma Announces Publication on the Safety, Efficacy and Novel LANCL2 Mechanism of Action of Omilancor in Inflammatory Bowel Diseases

This publication describes novel LANCL2-based immunoregulatory mechanisms that enhance regulatory T cells (Tregs) anti-inflammatory functions by amplifying IL-2 signaling and promote T cell metabolic reprogramming resulting in enhanced mitochondrial metabolism...

Read More

Research and White Papers
Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn’s Disease

Treating Autoimmune Diseases With LANCL2 Therapeutics: A Novel Immunoregulatory Mechanism for Patients With Ulcerative Colitis and Crohn’s Disease

Lanthionine synthetase C-like 2 (LANCL2) therapeutics have gained increasing recognition as a novel treatment modality for a wide range of autoimmune diseases. Genetic ablation of LANCL2 in mice results in severe inflammatory phenotypes in inflammatory bowel...

Read More